SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant þ
Filed by a Party other than the ¨
Check the appropriate box:
¨ Preliminary Proxy Statement
¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨ Definitive Proxy Statement
þ Definitive Additional Materials
¨ Soliciting Material under §240.14a-12
OPIANT PHARMACEUTICALS, INC.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ No fee required.
¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
◦Title of each class of securities to which transaction applies:
◦Aggregate number of securities to which transaction applies:
◦Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
◦Proposed maximum aggregate value of transaction:
◦Total fee paid:
¨ Fee paid previously with preliminary materials.
¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
1.Amount Previously Paid:
2.Form, Schedule or Registration Statement No.:
Additional Information Regarding Opiant Pharmaceuticals’ Annual Meeting of Stockholders to be Held on June 15, 2021
Opiant Pharmaceuticals issued the following press release on May 18, 2021, which relates to its proxy statement dated April 19, 2021, and furnished to its stockholders in connection with the solicitation of proxies for use at its annual meeting of stockholders to be held on Tuesday, June 15, 2021.
This supplement is being filed with the Securities and Exchange Commission and was made available to stockholders on May 19, 2021.
This supplement should be read in conjunction with Opiant Pharmaceuticals’ proxy statement dated April 19, 2021.
Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00 am, PDT
SANTA MONICA, CA, May 18, 2021 – Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that, due to the continuing public health concerns relating to the coronavirus (COVID-19) pandemic, and to protect the health and well-being of its shareholders, employees, and other stakeholders, Opiant's 2021 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The original date and time of the 2021 Annual Meeting, as well as the matters to be voted on at the 2021 Annual Meeting, remain unchanged.
The Company’s proxy statement describing the formal business to be conducted at the meeting is available on the Investors section of the Company’s website at: https://ir.opiant.com/static-files/90791c5a-5c1e-40df-ab4a-4e54cbb7630f
Shareholders who elect to virtually attend the meeting may do so as follows:
Virtual Meeting Date: Tuesday, June 15, 2021
Virtual Meeting Time: 9:00 a.m. (Pacific Time)
Virtual Meeting Link: Zoom Meeting
(Meeting ID: 919 3266 9149)
Join by telephone only
877 369 0926 US Toll-free
877 853 5247 US Toll-free
Meeting ID: 919 3266 9149
Find your local number: https://zoom.us/u/aO3gNgQ4J
Shareholders of record at the close of business on April 16, 2021, the record date for the 2021 Annual Meeting, are entitled to participate in the virtual meeting and will need their assigned 16-digit control number to vote shares electronically at the virtual meeting by submitting an email to: Admin12@astfinancial.com
Important Information for Voting Shares
Your vote is important. Whether or not shareholders plan to attend the virtual-only annual meeting, Opiant urges shareholders to vote and submit their proxies in advance of the meeting by one of the methods described in the proxy materials.
Shareholders of record with Internet access may submit proxies until 11:59 p.m., Eastern Time, on June 14, 2021, by following the instructions on your proxy cards or at www.voteproxy.com.
Shareholders who have already voted their shares do not need to vote them again because of this change in meeting format.
A list of shareholders entitled to vote at the 2021 Annual Meeting will be available for review by interested shareholders at the offices of the Company, 233 Wilshire Blvd., Suite 280, Santa Monica, CA 90401, beginning on June 5, 2021. Please contact the Company’s Investor Relations by sending an e-mail to firstname.lastname@example.org, if you wish to inspect the list prior to the meeting.
Attending the Annual Meeting as a Guest
Those without a control number may attend the virtual meeting as guests, but will not have the option to vote.
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
For more information visit: www.opiant.com.
# # #
Important Notice of Availability of Proxy Materials for the Stockholder Meeting of
OPIANT PHARMACEUTICALS, INC.
To Be Held On:
June 15, 2021 at 9:00 a.m.
233 Wilshire Blvd., Suite 280, Santa Monica, CA 90401
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting.
If you want to receive a paper or e-mail copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request as instructed below before 06/05/21.
Please visit http://www.astproxyportal.com/ast/21992/, where the following materials are available for view:
* Notice of Annual Meeting of Stockholders
* Proxy Statement
* Form of Electronic Proxy Card
* Annual Report on Form 10-K
| TO REQUEST MATERIAL: |
TELEPHONE: 888-Proxy-NA (888-776-9962) 718-921-8562 (for international callers)
| TO VOTE:|
ONLINE: To access your online proxy card, please visit www.voteproxy.com and follow the on-screen instructions or scan the QR code with your smartphone. You may enter your voting instructions at www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date.
IN PERSON: You may vote your shares in person by attending the Annual Meeting.
TELEPHONE: To vote by telephone, please visit www.voteproxy.com to view the materials and to obtain the toll free number to call.
MAIL: You may request a card by following the instructions above.
1.Election of Directors:
|2. Approval to issue greater than 20% of the common stock outstanding.|
|3. Ratification of Independent Registered Public Accounting Firm.|
| Craig Collard||4. Advisory Approval of our Executive Compensation|
| Richard Daly|
| Dr. Michael Sinclair||THE BOARD OF DIRECTORS RECOMMENDS A VOTE "FOR" THE LISTED NOMINEES, "FOR" PROPOSALS 2, 3 AND 4.|
|Please note that you cannot use this notice to vote by mail.|